查看購物車
  • Simplified Chinese
  • English
  • Japanese
封面
市場調查報告書
商品編碼
1869950

生物相似藥市場規模、佔有率和趨勢分析報告：按藥物類別、適應症、最終用途、地區和細分市場預測（2025-2033 年）

Biosimilars Market Size, Share & Trends Analysis Report By Drug Class (Monoclonal Antibodies (mAbs), Growth Factors & Hematopoietic Agents), By Indication, By End Use, By Region, And Segment Forecasts, 2025 - 2033
出版日期: | 出版商: Grand View Research | 英文 150 Pages | 商品交期: 2-10個工作天內

價格

生物相似藥市場摘要

2024年全球生物相似藥市場規模估計為3,392萬美元，預計2033年將達到1.5158億美元。

預計從 2025 年到 2033 年，該市場將以 18.27% 的複合年成長率成長。生物相似藥的成本效益和全球慢性病盛行率的不斷上升是推動該市場成長的主要因素。

此外，這些藥物易於生產，研發投入相對較低，且療效與原廠藥相當，可降低醫療成本。同時，生產成本的降低和需求的成長可能會促使生產商轉向生物相似藥以提高利潤，進一步刺激市場發展。生物相似藥可能含有略有不同的物質或藥物成分組合，但在療效和安全性方面與原廠生物製藥相似。

目前有多項法規用於評估生物相似藥的適用性和安全性。例如，美國食品藥物管理局(FDA) 的簡略新藥申請流程要求申請人以科學方式證明其產品的性能與參考生物製藥相當。這可以透過證明其產品與原廠藥在相似的時間內進入血液循環來體現。這些法規有助於建立公眾對生物相似藥的信任，並提高其市場佔有率。

此外，全球慢性病和非傳染性疾病盛行率的不斷上升預計將推動市場成長。根據世界衛生組織（世衛組織）2023年11月發布的統計數據，癌症、糖尿病和心臟病等非傳染性疾病每年導致4,100萬人死亡，其中77%發生在低收入和中等收入國家。

美國食品藥物管理局（FDA）預計2022年核准三種癌症生物相似藥，並於2023年上市。這些不斷擴大的市場機會正促使主要企業加大對生物相似藥研發的投入。例如，根據《今日商業》2022年4月發表的報導報道，百康生物製藥公司計劃將其研發支出增加10-15%，以推進其生物類似藥產品線的研發。此舉預計將在未來鞏固該公司的市場地位。生物相似藥的研發在製藥業正蓬勃發展。

目錄

第1章調查方法和範圍

第2章執行摘要

第3章 生物相似藥市場變數、趨勢與範圍

  • 市場體系展望
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 商業環境分析
    • 產業分析—波特五力分析
    • PESTLE分析
    • 管道分析

第4章 生物相似藥市場：藥物類別業務分析

  • 2024 年及 2033 年各藥物類別市佔率
  • 藥物類別細分儀表板
  • 按藥物類別分類的市場規模、預測和趨勢分析，2021-2033年
  • 單株抗體（mAbs）
  • 生長因子和造血因子
  • 胰島素及其類似物
  • 骨質疏鬆症/促進骨骼代謝的藥物
  • 其他

第5章 生物相似藥市場：適應症業務分析

  • 適應症市場佔有率，2024 年和 2033 年
  • 指示細分儀表板
  • 市場規模、預測與趨勢分析（按指標，2021-2033 年）
  • 自體免疫疾病（類風濕性關節炎、發炎性腸道疾病、乾癬、僵直性脊椎炎）
  • 腫瘤科（乳癌、結腸癌、淋巴瘤、肺癌、胃癌）
  • 糖尿病（1 型和 2 型）
  • 眼科疾病（滲出性老齡化黃斑部病變、糖尿病視網膜病變、眼瞼下垂）
  • 血液疾病/罕見血液疾病
  • 其他

第6章 生物相似藥市場：終端用戶業務分析

  • 2024 年及 2033 年最終用戶市場佔有率
  • 最終用戶細分儀表板
  • 按最終用途分類的市場規模、預測和趨勢分析（2021-2033 年）
  • 醫院
  • 專科藥房
  • 線上和零售通路

第7章 生物相似藥市場：區域估算與趨勢分析

  • 2024 年及 2033 年區域市佔率分析
  • 區域市場概覽
  • 市場規模及預測趨勢分析（2021-2033）：
  • 北美洲
    • 按國家/地區分類，2021-2033 年
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第8章 競爭情勢

  • 參與者概覽
  • 企業市場分析
  • 公司分類
  • 策略規劃
  • 公司簡介/上市公司
    • Amgen Inc.
    • F Hoffman-La Roche Ltd
    • Sandoz International GmbH
    • Dr. Reddy's Laboratories
    • Teva Pharmaceutical Industries Ltd
    • Pfizer Inc.
    • Samsung Biopis
    • Biocon
    • Viatris Inc.
    • Celltrion Healthcare Co.Ltd
    • AbbVie Inc.
Product Code: 978-1-68038-916-6

Biosimilars Market Summary

The global biosimilars market size was estimated at USD 33.92 million in 2024 and is projected to reach USD 151.58 million by 2033, growing at a CAGR of 18.27% from 2025 to 2033. The cost-effectiveness of biosimilar drugs and the prevalence of chronic disorders globally are major factors contributing to market growth.

In addition, these drugs are comparatively easy to produce since they require less investment in research and development while providing similar results. This can help cut down expenditures on health. Moreover, the reduction in production costs and increasing demand can encourage producers to shift to biosimilars due to increased profits, which can give a further boost to this market. Biosimilars may contain slightly different substances and combinations of medical ingredients, but they are considered similar to their reference biologics in terms of effectiveness and safety.

Several regulations are in place to assess the compatibility and safety of biosimilar drugs. For instance, the FDA's Abbreviated New Drug Application Process requires applicants to scientifically prove that the performance of their product is similar to the reference biologics. It can be demonstrated by proving that their product takes a similar time to reach the bloodstream as the original product. Such regulations can help build trust in these drugs and expand their market share.

Moreover, the increasing prevalence of chronic or non-communicable diseases across the globe is also expected to drive the market. According to statistics released by the World Health Organization in November 2023, non-communicable diseases, such as cancer, diabetes, and heart diseases, cause 41 million deaths every year, out of which 77% of fatalities belong to low- and middle-income countries.

The U.S. FDA approved three cancer-related biosimilars in 2022, which are expected to hit the market in 2023. These growing opportunities in this market are also encouraging key players to increase their investment in the research and development of biosimilars. For instance, according to an article published in Business Today in April 2022, Biocon Biologics planned to increase its R&D expenses by 10% to 15% to advance its pipeline of biosimilar molecules. The step is expected to help strengthen its future position in the market. There is a boom in the pharmaceutical industry in the development of biosimilar medications.

Global Biosimilars Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global biosimilars market report based on drug class, indication, end use and region:

  • Drug Class Outlook (Revenue, USD Billion, 2021 - 2033)
  • Monoclonal Antibodies (mAbs)
  • Growth Factors & Hematopoietic Agents
  • Insulin & Analogues
  • Osteoporosis / Bone Metabolism Agents
  • Others
  • Indication Outlook (Revenue, USD Billion, 2021 - 2033)
  • Autoimmune Disorders (RA, IBD, Psoriasis, Ankylosing Spondylitis)
  • Oncology (Breast, Colorectal, Lymphoma, Lung, Gastric)
  • Diabetes Mellitus (Type 1 & Type 2)
  • Ophthalmic Disorders (Wet AMD, DME, RVO)
  • Hematologic / Rare Blood Disorders
  • Others
  • End Use Outlook (Revenue, USD Billion, 2021 - 2033)
  • Hospitals
  • Specialty Pharmacies
  • Online & Retail Channels
  • Regional Outlook (Revenue, USD Billion, 2021 - 2033)
  • North America
    • U.S.
    • Canada
    • Mexico
  • Europe
    • UK
    • Germany
    • France
    • Italy
    • Spain
    • Denmark
    • Sweden
    • Norway
  • Asia Pacific
    • Japan
    • China
    • India
    • Australia
    • South Korea
    • Thailand
  • Latin America
    • Brazil
    • Argentina
  • Middle East & Africa
    • South Africa
    • Saudi Arabia
    • UAE
    • Kuwaita

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation & Scope
  • 1.2. Segment Definitions
    • 1.2.1. Drug Class
    • 1.2.2. Indication
    • 1.2.3. End Use
  • 1.3. Estimates and Forecast Timeline
  • 1.4. Research Methodology
  • 1.5. Information Procurement
    • 1.5.1. Purchased Database
    • 1.5.2. GVR's Internal Database
    • 1.5.3. Secondary Sources
    • 1.5.4. Primary Research
  • 1.6. Information Analysis
    • 1.6.1. Data Analysis Models
  • 1.7. Market Formulation & Data Visualization
  • 1.8. Model Details
    • 1.8.1. Commodity Flow Analysis
  • 1.9. List of Secondary Sources
  • 1.10. Objectives

Chapter 2. Executive Summary

  • 2.1. Market Snapshot
  • 2.2. Segment Snapshot
  • 2.3. Competitive Landscape Snapshot

Chapter 3. Biosimilars Market Variables, Trends, & Scope

  • 3.1. Market Lineage Outlook
  • 3.2. Market Dynamics
    • 3.2.1. Market Driver Analysis
    • 3.2.2. Market Restraint Analysis
  • 3.3. Business Environment Analysis
    • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
      • 3.3.1.1. Supplier Power
      • 3.3.1.2. Buyer Power
      • 3.3.1.3. Substitution Threat
      • 3.3.1.4. Threat of New Entrants
      • 3.3.1.5. Competitive Rivalry
    • 3.3.2. PESTLE Analysis
    • 3.3.3. Pipeline Analysis

Chapter 4. Biosimilars Market: Drug Class Business Analysis

  • 4.1. Drug Class Market Share, 2024 & 2033
  • 4.2. Drug Class Segment Dashboard
  • 4.3. Market Size & Forecasts and Trend Analysis, by Drug Class, 2021 to 2033 (USD Billion)
  • 4.4. Monoclonal Antibodies (mAbs)
    • 4.4.1. Monoclonal Antibodies (mAbs) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.5. Growth Factors & Hematopoietic Agents
    • 4.5.1. Growth Factors & Hematopoietic Agents Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.6. Insulin & Analogues
    • 4.6.1. Insulin & Analogues Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.7. Osteoporosis / Bone Metabolism Agents
    • 4.7.1. Osteoporosis / Bone Metabolism Agents Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 4.8. Others
    • 4.8.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 5. Biosimilars Market: Indication Business Analysis

  • 5.1. Indication Market Share, 2024 & 2033
  • 5.2. Indication Segment Dashboard
  • 5.3. Market Size & Forecasts and Trend Analysis, by Indication, 2021 to 2033 (USD Billion)
  • 5.4. Autoimmune Disorders (RA, IBD, Psoriasis, Ankylosing Spondylitis)
    • 5.4.1. Autoimmune Disorders (RA, IBD, Psoriasis, Ankylosing Spondylitis) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.5. Oncology (Breast, Colorectal, Lymphoma, Lung, Gastric)
    • 5.5.1. Oncology (Breast, Colorectal, Lymphoma, Lung, Gastric) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.6. Diabetes Mellitus (Type 1 & Type 2)
    • 5.6.1. Diabetes Mellitus (Type 1 & Type 2) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.7. Ophthalmic Disorders (Wet AMD, DME, RVO)
    • 5.7.1. Ophthalmic Disorders (Wet AMD, DME, RVO) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.8. Hematologic / Rare Blood Disorders
    • 5.8.1. Hematologic / Rare Blood Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 5.9. Others
    • 5.9.1. Others Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 6. Biosimilars Market: End Use Business Analysis

  • 6.1. End Use Market Share, 2024 & 2033
  • 6.2. End Use Segment Dashboard
  • 6.3. Market Size & Forecasts and Trend Analysis, by End Use, 2021 to 2033 (USD Billion)
  • 6.4. Hospitals
    • 6.4.1. Hospitals Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.5. Specialty Pharmacies
    • 6.5.1. Specialty Pharmacies Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 6.6. Online & Retail Channels
    • 6.6.1. Online & Retail Channels Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 7. Biosimilars Market: Regional Estimates & Trend Analysis

  • 7.1. Regional Market Share Analysis, 2024 & 2033
  • 7.2. Regional Market Dashboard
  • 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
  • 7.4. North America
    • 7.4.1. North America Biosimilars Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
    • 7.4.2. U.S.
      • 7.4.2.1. Key Country Dynamics
      • 7.4.2.2. Type Disease Prevalence
      • 7.4.2.3. Regulatory Framework
      • 7.4.2.4. Reimbursement Framework
      • 7.4.2.5. U.S. Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.4.3. Canada
      • 7.4.3.1. Key Country Dynamics
      • 7.4.3.2. Type Disease Prevalence
      • 7.4.3.3. Regulatory Framework
      • 7.4.3.4. Reimbursement Framework
      • 7.4.3.5. Canada Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.4.4. Mexico
      • 7.4.4.1. Key Country Dynamics
      • 7.4.4.2. Type Disease Prevalence
      • 7.4.4.3. Regulatory Framework
      • 7.4.4.4. Reimbursement Framework
      • 7.4.4.5. Mexico Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5. Europe
    • 7.5.1. Europe Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.2. UK
      • 7.5.2.1. Key Country Dynamics
      • 7.5.2.2. Type Disease Prevalence
      • 7.5.2.3. Regulatory Framework
      • 7.5.2.4. Reimbursement Framework
      • 7.5.2.5. UK Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.3. Germany
      • 7.5.3.1. Key Country Dynamics
      • 7.5.3.2. Type Disease Prevalence
      • 7.5.3.3. Regulatory Framework
      • 7.5.3.4. Reimbursement Framework
      • 7.5.3.5. Germany Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.4. France
      • 7.5.4.1. Key Country Dynamics
      • 7.5.4.2. Type Disease Prevalence
      • 7.5.4.3. Regulatory Framework
      • 7.5.4.4. Reimbursement Framework
      • 7.5.4.5. France Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.5. Italy
      • 7.5.5.1. Key Country Dynamics
      • 7.5.5.2. Type Disease Prevalence
      • 7.5.5.3. Regulatory Framework
      • 7.5.5.4. Reimbursement Framework
      • 7.5.5.5. Italy Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.6. Spain
      • 7.5.6.1. Key Country Dynamics
      • 7.5.6.2. Type Disease Prevalence
      • 7.5.6.3. Regulatory Framework
      • 7.5.6.4. Reimbursement Framework
      • 7.5.6.5. Spain Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.7. Denmark
      • 7.5.7.1. Key Country Dynamics
      • 7.5.7.2. Type Disease Prevalence
      • 7.5.7.3. Regulatory Framework
      • 7.5.7.4. Reimbursement Framework
      • 7.5.7.5. Denmark Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.8. Sweden
      • 7.5.8.1. Key Country Dynamics
      • 7.5.8.2. Type Disease Prevalence
      • 7.5.8.3. Regulatory Framework
      • 7.5.8.4. Reimbursement Framework
      • 7.5.8.5. Sweden Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.5.9. Norway
      • 7.5.9.1. Key Country Dynamics
      • 7.5.9.2. Type Disease Prevalence
      • 7.5.9.3. Regulatory Framework
      • 7.5.9.4. Reimbursement Framework
      • 7.5.9.5. Norway Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6. Asia Pacific
    • 7.6.1. Asia Pacific Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.2. Japan
      • 7.6.2.1. Key Country Dynamics
      • 7.6.2.2. Type Disease Prevalence
      • 7.6.2.3. Regulatory Framework
      • 7.6.2.4. Reimbursement Framework
      • 7.6.2.5. Japan Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.3. China
      • 7.6.3.1. Key Country Dynamics
      • 7.6.3.2. Type Disease Prevalence
      • 7.6.3.3. Regulatory Framework
      • 7.6.3.4. Reimbursement Framework
      • 7.6.3.5. China Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.4. India
      • 7.6.4.1. Key Country Dynamics
      • 7.6.4.2. Type Disease Prevalence
      • 7.6.4.3. Regulatory Framework
      • 7.6.4.4. Reimbursement Framework
      • 7.6.4.5. India Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.5. Australia
      • 7.6.5.1. Key Country Dynamics
      • 7.6.5.2. Type Disease Prevalence
      • 7.6.5.3. Regulatory Framework
      • 7.6.5.4. Reimbursement Framework
      • 7.6.5.5. Australia Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.6. South Korea
      • 7.6.6.1. Key Country Dynamics
      • 7.6.6.2. Type Disease Prevalence
      • 7.6.6.3. Regulatory Framework
      • 7.6.6.4. Reimbursement Framework
      • 7.6.6.5. South Korea Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.6.7. Thailand
      • 7.6.7.1. Key Country Dynamics
      • 7.6.7.2. Type Disease Prevalence
      • 7.6.7.3. Regulatory Framework
      • 7.6.7.4. Reimbursement Framework
      • 7.6.7.5. Thailand Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.7. Latin America
    • 7.7.1. Latin America Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.7.2. Brazil
      • 7.7.2.1. Key Country Dynamics
      • 7.7.2.2. Type Disease Prevalence
      • 7.7.2.3. Regulatory Framework
      • 7.7.2.4. Reimbursement Framework
      • 7.7.2.5. Brazil Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.7.3. Argentina
      • 7.7.3.1. Key Country Dynamics
      • 7.7.3.2. Type Disease Prevalence
      • 7.7.3.3. Regulatory Framework
      • 7.7.3.4. Reimbursement Framework
      • 7.7.3.5. Argentina Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.8. Middle East and Africa
    • 7.8.1. Middle East and Africa Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.2. South Africa
      • 7.8.2.1. Key Country Dynamics
      • 7.8.2.2. Type Disease Prevalence
      • 7.8.2.3. Regulatory Framework
      • 7.8.2.4. Reimbursement Framework
      • 7.8.2.5. South Africa Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.3. Saudi Arabia
      • 7.8.3.1. Key Country Dynamics
      • 7.8.3.2. Type Disease Prevalence
      • 7.8.3.3. Regulatory Framework
      • 7.8.3.4. Reimbursement Framework
      • 7.8.3.5. Saudi Arabia Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.4. UAE
      • 7.8.4.1. Key Country Dynamics
      • 7.8.4.2. Type Disease Prevalence
      • 7.8.4.3. Regulatory Framework
      • 7.8.4.4. Reimbursement Framework
      • 7.8.4.5. UAE Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
    • 7.8.5. Kuwait
      • 7.8.5.1. Key Country Dynamics
      • 7.8.5.2. Type Disease Prevalence
      • 7.8.5.3. Regulatory Framework
      • 7.8.5.4. Reimbursement Framework
      • 7.8.5.5. Kuwait Biosimilars Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 8. Competitive Landscape

  • 8.1. Participant Overview
  • 8.2. Company Market Position Analysis
  • 8.3. Company Categorization
  • 8.4. Strategy Mapping
  • 8.5. Company Profiles/Listing
    • 8.5.1. Amgen Inc.
      • 8.5.1.1. Overview
      • 8.5.1.2. Financial Performance
      • 8.5.1.3. Product Benchmarking
      • 8.5.1.4. Strategic Initiatives
    • 8.5.2. F Hoffman-La Roche Ltd
      • 8.5.2.1. Overview
      • 8.5.2.2. Financial Performance
      • 8.5.2.3. Product Benchmarking
      • 8.5.2.4. Strategic Initiatives
    • 8.5.3. Sandoz International GmbH
      • 8.5.3.1. Overview
      • 8.5.3.2. Financial Performance
      • 8.5.3.3. Product Benchmarking
      • 8.5.3.4. Strategic Initiatives
    • 8.5.4. Dr. Reddy's Laboratories
      • 8.5.4.1. Overview
      • 8.5.4.2. Financial Performance
      • 8.5.4.3. Product Benchmarking
      • 8.5.4.4. Strategic Initiatives
    • 8.5.5. Teva Pharmaceutical Industries Ltd
      • 8.5.5.1. Overview
      • 8.5.5.2. Financial Performance
      • 8.5.5.3. Product Benchmarking
      • 8.5.5.4. Strategic Initiatives
    • 8.5.6. Pfizer Inc.
      • 8.5.6.1. Overview
      • 8.5.6.2. Financial Performance
      • 8.5.6.3. Product Benchmarking
      • 8.5.6.4. Strategic Initiatives
    • 8.5.7. Samsung Biopis
      • 8.5.7.1. Overview
      • 8.5.7.2. Financial Performance
      • 8.5.7.3. Product Benchmarking
      • 8.5.7.4. Strategic Initiatives
    • 8.5.8. Biocon
      • 8.5.8.1. Overview
      • 8.5.8.2. Financial Performance
      • 8.5.8.3. Product Benchmarking
      • 8.5.8.4. Strategic Initiatives
    • 8.5.9. Viatris Inc.
      • 8.5.9.1. Overview
      • 8.5.9.2. Financial Performance
      • 8.5.9.3. Product Benchmarking
      • 8.5.9.4. Strategic Initiatives
    • 8.5.10. Celltrion Healthcare Co.Ltd
      • 8.5.10.1. Overview
      • 8.5.10.2. Financial Performance
      • 8.5.10.3. Product Benchmarking
      • 8.5.10.4. Strategic Initiatives
    • 8.5.11. AbbVie Inc.
      • 8.5.11.1. Overview
      • 8.5.11.2. Financial Performance
      • 8.5.11.3. Product Benchmarking
      • 8.5.11.4. Strategic Initiatives

List of Tables

  • Table 1 List Of Secondary Sources
  • Table 2 List Of Abbreviations
  • Table 3 Global Biosimilars Market, By Region, 2021 - 2033 (USD Billion)
  • Table 4 Global Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 5 Global Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 6 Global Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 7 North America Biosimilars Market, By Country, 2021 - 2033 (USD Billion)
  • Table 8 North America Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 9 North America Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 10 North America Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 11 US Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 12 US Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 13 US Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 14 Canada Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 15 Canada Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 16 Canada Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 17 Mexico Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 18 Mexico Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 19 Mexico Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 20 Europe Biosimilars Market, By Country, 2021 - 2033 (USD Billion)
  • Table 21 Europe Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 22 Europe Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 23 Europe Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 24 UK Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 25 UK Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 26 UK Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 27 Germany Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 28 Germany Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 29 Germany Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 30 France Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 31 France Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 32 France Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 33 Italy Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 34 Italy Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 35 Italy Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 36 Spain Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 37 Spain Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 38 Spain Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 39 Norway Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 40 Norwa Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 41 Norwa Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 42 Denmark Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 43 Denmark Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 44 Denmark Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 45 Sweden Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 46 Swede Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 47 Swede Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 48 Asia Pacific Biosimilars Market, By Country, 2021 - 2033 (USD Billion)
  • Table 49 Asia Pacific Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 50 Asia Pacific Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 51 Asia Pacific Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 52 Japan Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 53 Japan Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 54 Japan Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 55 China Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 56 China Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 57 China Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 58 India Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 59 India Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 60 India Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 61 Australia Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 62 Australia Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 63 Australia Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 64 South Korea Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 65 South Korea Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 66 South Korea Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 67 Thailand Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 68 Thailand Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 69 Thailand Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 70 Latin America Biosimilars Market, By Country, 2021 - 2033 (USD Billion)
  • Table 71 Latin America Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 72 Latin America Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 73 Latin America Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 74 Brazil Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 75 Brazil Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 76 Brazil Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 77 Argentina Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 78 Argentina Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 79 Argentina Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 80 Middle East & Africa Biosimilars Market, By Country, 2021 - 2033 (USD Billion)
  • Table 81 Middle East & Africa Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 82 Middle East & Africa Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 83 Middle East & Africa Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 84 South Africa Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 85 South Africa Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 86 South Africa Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 87 Saudi Arabia Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 88 Saudi Arabia Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 89 Saudi Arabia Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 90 UAE Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 91 UAE Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 92 UAE Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)
  • Table 93 Kuwait Biosimilars Market, By Drug Class, 2021 - 2033 (USD Billion)
  • Table 94 Kuwait Biosimilars Market, By Indication, 2021 - 2033 (USD Billion)
  • Table 95 Kuwait Biosimilars Market, By End Use, 2021 - 2033 (USD Billion)

List of Figures

  • Fig. 1 Biosimilars market segmentation
  • Fig. 2 Market research process
  • Fig. 3 Data triangulation techniques
  • Fig. 4 Primary research pattern
  • Fig. 5 Market research approaches
  • Fig. 6 Value-chain-based sizing & forecasting
  • Fig. 7 Market formulation & validation
  • Fig. 8 Market snapshot
  • Fig. 9 Therapeutic approach and disease outlook (USD Billion)
  • Fig. 10 Competitive landscape
  • Fig. 11 Biosimilars market dynamics
  • Fig. 12 Biosimilars market: Porter's five forces analysis
  • Fig. 13 Biosimilars market: PESTLE analysis
  • Fig. 14 Drug Class market, 2021 - 2033 (USD Billion)
  • Fig. 15 Monoclonal Antibodies (mAbs) Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 16 Growth Factors & Hematopoietic Agents Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 17 Insulin & Analogues Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 18 Osteoporosis / Bone Metabolism Agents Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 19 Others Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • Fig. 20 Indication market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 21 Autoimmune Disorders (RA, IBD, Psoriasis, Ankylosing Spondylitis) market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 22 Oncology (Breast, Colorectal, Lymphoma, Lung, Gastric) market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 23 Diabetes Mellitus (Type 1 & Type 2) market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 24 Ophthalmic Disorders (Wet AMD, DME, RVO) market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 25 Hematologic / Rare Blood Disorders market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 26 Others market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 27 End Use market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 28 Hospitals market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 29 Specialty Pharmacies market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 30 Online & Retail Channels market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 31 Biosimilars market revenue, by region
  • Fig. 32 Regional marketplace: Key takeaways
  • Fig. 33 North America biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 34 US country dynamics
  • Fig. 35 US biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 36 Canada country dynamics
  • Fig. 37 Canada biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 38 Mexico country dynamics
  • Fig. 39 Mexico biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 40 Europe biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 41 UK country dynamics
  • Fig. 42 UK biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 43 Germany country dynamics
  • Fig. 44 Germany biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 45 France country dynamics
  • Fig. 46 France biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 47 Italy country dynamics
  • Fig. 48 Italy biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 49 Spain country dynamics
  • Fig. 50 Spain biosimilars market, 2021 - 2033 (USD Billion)
  • Fig. 51 Norway country dynamics
  • Fig. 52 Norway biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 53 Sweden country dynamics
  • Fig. 54 Sweden biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 55 Denmark country dynamics
  • Fig. 56 Denmark biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 57 Asia Pacific biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 58 Japan country dynamics
  • Fig. 59 Japan biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 60 China country dynamics
  • Fig. 61 China biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 62 India country dynamics
  • Fig. 63 India biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 64 Australia country dynamics
  • Fig. 65 Australia biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 66 South Korea country dynamics
  • Fig. 67 South Korea biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 68 Thailand country dynamics
  • Fig. 69 Thailand biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 70 Latin America biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 71 Brazil country dynamics
  • Fig. 72 Brazil biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 73 Argentina country dynamics
  • Fig. 74 Argentina biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 75 MEA biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 76 South Africa country dynamics
  • Fig. 77 South Africa biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 78 Saudi Arabia country dynamics
  • Fig. 79 Saudi Arabia biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 80 UAE country dynamics
  • Fig. 81 UAE biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 82 Kuwait country dynamics
  • Fig. 83 Kuwait biosimilars market estimates and forecasts, 2021 - 2033 (USD Billion)
  • Fig. 84 Company categorization
  • Fig. 85 Company market position analysis
  • Fig. 86 Strategic framework